Evaluation of NPP1 as a Novel Biomarker of Coronary Artery Disease: A Pilot Study in Human Beings

Amir Hooshang Mohammadpour ^1,2 , Saeed Nazemi ³, Fatemeh Mashhadi ², Atefeh Rezapour ², Mohammad Afshar ^4,5, Sepideh Afzalnia ³, Afsaneh Mohammadi ³, Hamid Reza Mashreghi Moghadam ⁶, Maryam Moradian ⁷, Seyed Mohammad Hasan Moallem ⁸, Saeed Falahaty ², Azadeh Zayerzadeh ², Sepideh Elyasi ^1,2 *

Cited by CrossRef: 1

1- Wu X, Di F, Shen S, Wang S, Li Q, Dong Z, Guan J, He J, Wang Y. Levels of serum ecto‐nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) predicts severity of abdominal aortic calcification in end‐stage renal disease patients receiving regular dialysis. Hemodialysis International. 2022;26(1):23 [Crossref]

2- Yazdani A, Pletsch M, Chorbajian A, Zitser D, Rai V, Agrawal D. Biomarkers to monitor the prognosis, disease severity, and treatment efficacy in coronary artery disease. Expert Review of Cardiovascular Therapy. 2023;21(10):675 [Crossref]

3- Pavithra R, Sangeetha T, Velayuthaprabhu S, Anand A. A literature survey on the biomarkers of cardiovascular disease. Int J Acad Med. 2021;7(3):141 [Crossref]